Compare PTGX & SEMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | SEMR |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 1.8B |
| IPO Year | 2016 | 2021 |
| Metric | PTGX | SEMR |
|---|---|---|
| Price | $87.50 | $11.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $90.56 | $13.80 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | $209,217,000.00 | ★ $428,627,000.00 |
| Revenue This Year | N/A | $20.35 |
| Revenue Next Year | $296.47 | $14.87 |
| P/E Ratio | $119.12 | ★ N/A |
| Revenue Growth | N/A | ★ 19.87 |
| 52 Week Low | $33.70 | $6.56 |
| 52 Week High | $96.54 | $18.74 |
| Indicator | PTGX | SEMR |
|---|---|---|
| Relative Strength Index (RSI) | 49.09 | 80.41 |
| Support Level | $84.11 | $11.83 |
| Resistance Level | $96.54 | $11.88 |
| Average True Range (ATR) | 3.20 | 0.03 |
| MACD | -0.82 | -0.15 |
| Stochastic Oscillator | 24.12 | 42.11 |
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.